The Motley Fool

Why I believe you can double your money with Footsie champion GlaxoSmithKline plc

Image source: Getty Images.

GlaxoSmithKline (LSE: GSK) is one of the FTSE 100’s income champions. Despite stagnating earnings, over the past four years the company has paid out 80p per share annually to investors without fail for an average dividend yield over the period of 5.6%, around 1.8% higher than the FTSE 100 average over the period. 

However, recently shares in the pharmaceutical giant have come under pressure. Analysts have started to speculate that the group’s dividend record is under threat as new CEO Emma Walmsley eyes up possible acquisitions. 

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Buying growth 

Since 2012, Glaxo’s earnings have been treading water. The company reported earnings per share of 111p for 2012 then they fell to a low of 76p before rebounding to 102p last year. Analysts have pencilled in earnings per share of 110p for full-year 2017. 

Although other factors have contributed, the loss of exclusive manufacturing rights for the company’s blockbuster Advair drug has been responsible for the bulk of the earnings slide and Glaxo has also been underinvesting for years. The group’s research spend as a percentage of sales is less than 14% compared to its peer average of around 18%. AstraZeneca, Merck, and Bristol-Myers Squibb spent more than 25% of their revenues on R&D in 2016.

Walmsley wants to reverse this trend. She believes that Glaxo should move back to its scientific roots and search for the blockbuster drugs of the future. To this end, the new CEO has dropped 30 development programmes to focus on what she believes will be the real winners. 

She is also eyeing up acquisitions. Management has said it will take a look a Pfizer‘s consumer healthcare business as well as potentially acquiring the rest of the consumer joint venture it has with Novartis. Moreover, for the first time in over nine decades, the group has set up a team to look at smaller acquisitions in the domestic UK market. 

Cash flow crunch 

If Glaxo wants to ramp up spending, I believe management will have to cut the group’s dividend to free up cash. This might be unpalatable for income investors, but I think it will result in better long-term capital gains. 

As growth returns, the market should re-rate the stock to a more attractive multiple, producing potentially better returns than the current 5.9% dividend yield. For example, right now shares in Glaxo are trading at a forward P/E of 12.7 compared to the pharmaceuticals industry sector average of 18.8. If the market re-rates the stock on growth expectations up to the sector average, the shares could be worth 2,068p, a gain of 53% from current levels. 

Deals could help push the stock higher still. Pfizer’s consumer goods division generates around $3.4bn per annum in sales and a profit margin of around 20% suggests that this could boost Glaxo’s bottom line by around $700m, or approximately 10%. Buying the rest of the business with Novartis could add an extra 10% after extracting synergies. 

According to my figures, these deals could boost earnings per share to around 140p. At a sector average valuation, this implies a share price of more than 2,630p, nearly 100% above current levels. 

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

Rupert Hargreaves owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.